TL;DR
This study investigates the utility of ultrasound attenuation coefficient (ATT) as a non-invasive marker for assessing liver involvement, specifically steatosis, in children and adolescents with Wilson's disease (WD). The findings suggest that ATT is a valuable tool for this purpose and that combining it with other non-invasive markers like APRI, FIB-4, and SWM may further enhance diagnostic accuracy.
What Problem Does This Paper Address?
Wilson's disease (WD) is a genetic disorder characterized by copper accumulation, primarily in the liver, leading to a spectrum of liver damage including steatosis, inflammation, fibrosis, and cirrhosis. While liver biopsy is the gold standard for assessing these pathological changes, it's invasive and often difficult to perform in children, especially those with neurological manifestations. Current non-invasive methods like transient elastography (TE) and 2D shear wave elastography (2D-SWE) primarily focus on liver fibrosis and cirrhosis, overlooking early steatosis, which is a common initial sign of liver involvement in WD. This paper aims to address this gap by exploring the potential of the ultrasound attenuation coefficient (ATT) as a non-invasive index to quantify liver steatosis in pediatric WD patients.
Methods
The researchers conducted a retrospective observational study, collecting data from 62 children and adolescents diagnosed with WD. They utilized ultrasound-based modalities to measure the attenuation coefficient (ATT) and shear wave measurement (SWM). Additionally, they collected laboratory data to calculate the AST to platelet ratio index (APRI) and fibrosis 4 (FIB-4) score, which are established non-invasive markers for liver fibrosis.
To stratify liver involvement, patients were divided into three groups based on serum levels of collagen type IV (CIV), hyaluronic acid (HA), laminin (LN), and precollagen type III N-terminal peptide (PIIINP):
- Group 1: No abnormalities in these markers.
- Group 2: Elevation in 1 or 2 of these markers.
- Group 3: Elevation in 3 or 4 of these markers.
The study then compared ATT, SWM, APRI, and FIB-4 levels across these groups. Spearman's correlation analysis was used to assess the relationship between ATT and SWM, as well as ATT and triglyceride (TG). Receiver operating characteristic (ROC) curves were employed to evaluate the diagnostic efficacy of ATT alone and in combination with other markers for assessing hepatic steatosis.
Datasets
The study utilized data from 62 children and adolescents diagnosed with Wilson's disease, collected retrospectively from the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine between May 2022 and August 2022. No new benchmark datasets were introduced.
Key Insights and Ideas
- ATT as a Promising Non-Invasive Marker: The study highlights ATT's potential as a sensitive and reproducible non-invasive tool for assessing early liver steatosis in pediatric WD patients, a stage often overlooked by other methods.
- Early Steatosis is Key: The research emphasizes that hepatocellular steatosis is a common early pathological change in WD, making its early detection and quantification crucial for timely intervention.
- Synergistic Power of Combined Markers: While ATT shows good diagnostic efficacy on its own, combining it with established fibrosis markers (APRI, FIB-4) and SWM appears to improve diagnostic performance, suggesting a multi-modal approach is beneficial.
- SWM's Limited Role in Early Stages: The weak correlation between ATT and SWM suggests that SWM might not be as sensitive for detecting early steatosis, aligning with the understanding that fibrosis is a later stage of WD progression.
Key Results
- ATT levels showed significant differences across the three groups of WD patients based on liver involvement stratification (P<0.001).
- The area under the ROC curve (AUC) for ATT in diagnosing hepatic steatosis was 0.714 (Group 1 vs. Group 2), 0.712 (Group 2 vs. Group 3), and 0.867 (Group 1 vs. Group 3).
- For the diagnosis of hepatic steatosis in Group 1 versus Group 2, ATT achieved a sensitivity of 89.47% with a cutoff value of 0.73 dB/cm/MHz.
- No significant correlation was found between ATT and triglyceride (TG) levels (p=0.154).
- A weak negative correlation was observed between ATT and SWM (p = -0.374, P=0.003).
- The combination of ATT with APRI and FIB-4, or ATT with SWM, APRI, and FIB-4, showed improved diagnostic efficacy compared to ATT alone in Group 1 versus Group 2 (both P=0.038).
Limitations and Future Work
The authors acknowledge several limitations:
- Clinical Stratification: Liver involvement was stratified using serological markers for fibrosis rather than liver biopsy, which is often infeasible in WD patients with neurological impairments.
- Age Range and Growth: The study included pediatric patients aged 5-18 years, who are undergoing rapid growth and development. This limited sample size and age range may influence the results, and subgroup analysis based on age was not performed.
- Future Directions: The authors suggest that further investigation with larger sample sizes and potentially including younger children is warranted. They also propose that combining ATT with APRI, FIB-4, and SWM could further improve the diagnostic efficacy for early hepatocellular steatosis assessment in WD patients.
Summary updated